Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biogen Idec up on anticipated earnings

Biogen Idec (NASDAQ:BIIB) climbed $4 to $59.22 on Monday after it announced it expects 2007

Read the full 158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE